注册
CN
首页 > 产品中心 > 抗体 > XtenNano®纳米抗体

Anti-Human C4B Recombinant Nanobody (SAA3062) (HY567013)

价格:
规格：
  • 50ug
  • 100ug
  • 1mg
数量：
联系我们
一键复制产品信息

  • 概述

  • 图片

  • 参考文献

  • 产品说明书

概述
货号HY567013
品牌abinScience
种属反应性Human
应用ELISA, IF
宿主Alpaca
同种型VHH-His
克隆号SAA3062
克隆类型Monoclonal
靶标RecName: Full=Complement C4-B; AltName: Full=Basic complement C4; AltName: Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3; Contains: RecName: Full=Complement C4 beta chain; Contains: RecName: Full=Complement C4-B alpha chain; Contains: RecName: Full=C4a anaphylatoxin; Contains: RecName: Full=Complement C4b-B; Contains: RecName: Full=C4d-B; Contains: RecName: Full=Complement C4 gamma chain; Flags: Precursor, C4B, Basic complement C4; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3, /evidence=ECO:0000250|UniProtKB:P0C0L4., Complement C4 beta chain. /id=PRO_0000042699., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., Uncharacterized conserved protein YfaS, alpha-2-macroglobulin family [General function prediction only]; COG2373, /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., N-linked (GlcNAc...) asparagine. /evidence=ECO:0000269|PubMed:12754519., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., S -> Y (in allotype C4B-long; dbSNP:rs139889867). /evidence=ECO:0000269|PubMed:14574404, ECO:0000269|Ref.2. /id=VAR_023729., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., P -> L (in allotype C4B1-hi). /id=VAR_069160., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., Interchain (with C-820). /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000269|PubMed:6167582. /id=PRO_0000042700., Complement C4-B alpha chain. /id=PRO_0000042701., C4a anaphylatoxin. /id=PRO_0000042702., Anaphylatoxin homologous domain; C3a, C4a and C5a anaphylatoxins are protein fragments generated enzymatically in serum during activation of complement molecules C3, C4, and C5. They induce smooth muscle contraction. These fragments are homologous to...; cd00017, Anaphylatoxin-like. /evidence=ECO:0000255|PROSITE-ProRule:PRU00022., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0000250|UniProtKB:P0C0L4., R -> S (in Ref. 3; AAR89101). /evidence=ECO:0000305., /evidence=ECO:0000250|UniProtKB:P0C0L4., R -> Q (in Ref. 3; AAR89127). /evidence=ECO:0000305., Cleavage; by C1S, MASP2 and GZMK. /evidence=ECO:0000250|UniProtKB:P0C0L4., Complement C4b-B. /id=PRO_0000042703., Alpha-2-macroglobulin family; pfam00207, Interchain (with C-567). /evidence=ECO:0000250|UniProtKB:P0C0L4., N-linked (GlcNAc...) asparagine. /evidence=ECO:0000255., Interchain (with C-1590). /evidence=ECO:0000250|UniProtKB:P0C0L4., T -> A (in allotype C4B-long and allotype C4B2; dbSNP:rs796750528). /evidence=ECO:0000269|PubMed:14574404, ECO:0000269|Ref.2, ECO:0000269|Ref.3. /id=VAR_023730., Phosphoserine. /evidence=ECO:0000250|UniProtKB:P0C0L4., C4d-B. /id=PRO_0000042704., VT -> LQ (in Ref. 1; AAA99717). /evidence=ECO:0000305., A-macroglobulin TED domain; pfam07678, Isoglutamyl cysteine thioester (Cys-Gln)., Q -> E (in Ref. 8; AA sequence, 9; AA sequence and 10; AA sequence). /evidence=ECO:0000305., G -> D (in allotype C4B2 and allotype C4B5-Rg1; dbSNP:rs2258218). /evidence=ECO:0000269|PubMed:6546707, ECO:0000269|Ref.3. /id=VAR_023731., SQ -> IA (in Ref. 9; AA sequence). /evidence=ECO:0000305., L->P: No effect on hemolytic activity, nor on C1-dependent binding to IgG. /evidence=ECO:0000269|PubMed:2395880., S->C: 30-40% decrease in hemolytic activity and C1-dependent binding to IgG. /evidence=ECO:0000269|PubMed:2395880., I->A: 50-60% decrease in hemolytic activity and C1-dependent binding to IgG. /evidence=ECO:0000269|PubMed:2395880., H->A: 20% decrease in hemolytic activity, 2-fold increase in C1-dependent binding to IgG. /evidence=ECO:0000269|PubMed:2395880., H->D: 2.5-3 fold-decrease in hemolytic activity, 3-fold increase in C1-dependent binding to IgG. /evidence=ECO:0000269|PubMed:2395880., Responsible for effective binding to form amide bonds with immune aggregates or protein antigens. /evidence=ECO:0000269|PubMed:8538770., S -> N (in allotype C4B1a; dbSNP:rs2746414). /evidence=ECO:0000269|PubMed:14989716. /id=VAR_023732., A -> V (in allotype C4B5-Rg1; dbSNP:rs2229403). /evidence=ECO:0000269|PubMed:14989716. /id=VAR_023734., R -> L (in allotype C4B5-Rg1; dbSNP:rs2229409). /evidence=ECO:0000269|PubMed:14989716. /id=VAR_023735., H -> V (in Ref. 9; AA sequence and 13; AA sequence). /evidence=ECO:0000305., R -> V (in Ref. 9; AA sequence and 13; AA sequence). /evidence=ECO:0000305., I -> F (in allotype C4B1-SC01; dbSNP:rs2023616). /evidence=ECO:0000269|PubMed:8575831. /id=VAR_069161., N-linked (GlcNAc...) asparagine. /evidence=ECO:0000269|PubMed:16740002., N-linked (GlcNAc...) asparagine. /evidence=ECO:0000269|PubMed:14760718., Interchain (with C-1566). /evidence=ECO:0000250|UniProtKB:P0C0L4., Sulfotyrosine. /evidence=ECO:0000269|PubMed:3944109., Sulfotyrosine. /evidence=ECO:0000269|PubMed:3944109., Sulfotyrosine. /evidence=ECO:0000269|PubMed:3944109., /id=PRO_0000042705., Complement C4 gamma chain. /id=PRO_0000042706., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000250|UniProtKB:P0C0L4., A-macroglobulin receptor binding domain; pfam07677, /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., Interchain (with C-1394). /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., NTR/C345C domain, complement C4 subfamily; The NTR domain found in complement C4 is also known as the C345C domain because it occurs at the C-terminus of complement C3, C4 and C5. Complement C4 is a key player in the activation of the component classical...; cd03584, Interchain (with C-876). /evidence=ECO:0000250|UniProtKB:P0C0L4., NTR. /evidence=ECO:0000255|PROSITE-ProRule:PRU00295., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., T -> RA (in Ref. 1; AAA99717). /evidence=ECO:0000305., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., H -> Q (in Ref. 1; AAA99717). /evidence=ECO:0000305., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0007829|PDB:6YSQ., /evidence=ECO:0000250|UniProtKB:P0C0L4., /evidence=ECO:0007829|PDB:6YSQ.
内毒素水平Please contact with the lab for this information.
纯度>95% as determined by SDS-PAGE.
纯化方式Purified by Nickel column
Accession号P0C0L5
状态Liquid
保存溶液 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
重悬Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
产品使用信息
应用方法 稀释比例
ELISA 1:2000-1:20000
稳定性和存储Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
NoteFor research use only
图片
参考文献
产品说明书
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项，自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐

获取报价

Anti-Human C4B Recombinant Nanobody (SAA3062)

  • 7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言

  • 武汉东湖新技术开发区神墩四路666号研发楼B区3层东

  • 24小时产品查询

    24小时产品查询

  • 24小时产品查询

    扫一扫关注我们

  • 24小时产品查询

    专属渠道经理

Copyright © 2026 武汉艾必赛生物科技有限公司版权所有 所有产品仅可用于工业或者科研等非医疗目的。
鄂ICP备2023002448号-2